Myriad Genetics (MYGN) Cash from Operations (2009 - 2026)

Myriad Genetics (MYGN) has 18 years of Cash from Operations data on file, last reported at 15700000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 15700000.0, up 3.68% year-over-year; the trailing twelve-month figure through Mar 2026 was 2400000.0 (up 137.5% YoY), and the FY2025 annual result was 1800000.0, up 120.69% from the prior year.
• Cash from Operations fell to 15700000.0 in Q1 2026 per MYGN's latest filing, from 10600000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 21100000.0 in Q3 2025 and troughed at 54700000.0 in Q4 2023.
• A 5-year average of 14105882.35 and a median of 13600000.0 in 2025 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations sank 1029.55% in 2022, then surged 2914.29% in 2025.
• A 5-year view of Cash from Operations shows it stood at 7300000.0 in 2022, then tumbled by 649.32% to 54700000.0 in 2023, then surged by 112.07% to 6600000.0 in 2024, then soared by 60.61% to 10600000.0 in 2025, then tumbled by 248.11% to 15700000.0 in 2026.
• Business Quant data shows MYGN's Cash from Operations at 15700000.0 in Q1 2026, 10600000.0 in Q4 2025, and 21100000.0 in Q3 2025.